"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents inhibiting the effect of narcotics on the central nervous system.
| Descriptor ID |
D009292
|
| MeSH Number(s) |
D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
|
| Concept/Terms |
Narcotic Antagonists- Narcotic Antagonists
- Antagonists, Narcotic
- Opioid Receptor Antagonists
- Antagonists, Opioid Receptor
- Receptor Antagonists, Opioid
- Opioid Antagonists
- Antagonists, Opioid
|
Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".
This graph shows the total number of publications written about "Narcotic Antagonists" by people in this website by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1997 | 2 | 2 | 4 |
| 1998 | 3 | 1 | 4 |
| 1999 | 3 | 1 | 4 |
| 2000 | 2 | 1 | 3 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 4 | 1 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 4 | 0 | 4 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 2 | 6 |
| 2014 | 2 | 0 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 3 | 2 | 5 |
| 2019 | 1 | 1 | 2 |
| 2020 | 4 | 5 | 9 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 4 | 4 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles.
-
Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study. Harm Reduct J. 2024 Dec 20; 21(1):220.
-
Perceptions Toward Naloxone Among Patients With Cancer Receiving Opioids. J Pain Symptom Manage. 2024 Dec; 68(6):e500-e507.
-
96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. Int J Drug Policy. 2024 May; 127:104390.
-
Patients' willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States. J Am Pharm Assoc (2003). 2024 May-Jun; 64(3):102062.
-
Efforts to Improve Naloxone Co-Prescription for Patients With Cancer Pain at Risk of Opioid Overdose. J Palliat Med. 2023 07; 26(7):969-973.
-
Naloxone Over the Counter: Increasing Opportunities and Challenges for Health Providers. Am J Med. 2023 06; 136(6):504-506.
-
Effects of the cannabinoid CB1-receptor neutral antagonist AM4113 and antagonist/inverse agonist rimonabant on fentanyl discrimination in male rats. Drug Alcohol Depend. 2022 11 01; 240:109646.
-
Intention to get naloxone among?patients prescribed opioids for chronic pain. Harm Reduct J. 2022 Sep 22; 19(1):104.
-
HDAC6 Inhibition Reverses Cisplatin-Induced Mechanical Hypersensitivity via Tonic Delta Opioid Receptor Signaling. J Neurosci. 2022 10 19; 42(42):7862-7874.
-
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. Eur J Clin Pharmacol. 2022 Jun; 78(6):965-973.